Tumor Biology

, Volume 34, Issue 3, pp 1913–1918 | Cite as

Overexpression of ARK5 is associated with poor prognosis in hepatocellular carcinoma

Research Article
First Online:
Received:
Accepted:

Abstract

ARK5 overexpression has been reported in a variety of human cancers. However, the role of ARK5 in hepatocellular carcinoma (HCC) remains unclear. The aim of the present study is to analyze the ARK5 protein expression in HCC tissue samples and to assess its prognostic significance for HCC. ARK5 mRNA and protein expression were determined by real-time quantitative reverse transcriptase–polymerase chain reaction and Western blot in 20 pairs of fresh frozen HCC tissues and corresponding non-cancerous tissues. In addition, ARK5 expression was analyzed by immunohistochemistry in 130 clinicopathologically characterized HCC cases. The correlation of ARK5 expression with patients’ survival rate was assessed by Kaplan–Meier and Cox regression. Our results showed that the expression levels of ARK5 mRNA and protein in HCC tissues were both significantly higher than those in non-cancerous tissues. Our results showed that the high expression of ARK5 in HCC was related to tumor size (p = 0.005), histological differentiation (p = 0.047), and tumor stage (p = 0.005). Kaplan–Meier survival analysis showed that a high expression level of ARK5 resulted in a significantly poor prognosis of HCC patients. Multivariate analysis revealed that ARK5 expression level was an independent prognostic parameter for the overall survival rate of HCC patients. In conclusion, ARK5 might play a positive role in tumor development and could serve as an independent predictor of poor prognosis for HCC.

Keywords

ARK5 Hepatocellular carcinoma Biomarker Prognosis 
This is a preview of subscription content, log in to check access.

Notes

Conflict of interest

None.

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi: 10.3322/caac.20107.PubMedCrossRefGoogle Scholar
  2. 2.
    Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.PubMedCrossRefGoogle Scholar
  3. 3.
    Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40:225–35.PubMedCrossRefGoogle Scholar
  4. 4.
    Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell. 2004;5:215–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Suzuki A, Kusakai G, Kishimoto A, Lu J, Ogura T, Lavin MF, et al. Identification of a novel protein kinase mediating Akt survival signaling to the ATM protein. J Biol Chem. 2003;278:48–53. doi: 10.1074/jbc.M206025200.PubMedCrossRefGoogle Scholar
  6. 6.
    Suzuki A, Lu J, Kusakai G, Kishimoto A, Ogura T, Esumi H. ARK5 is a tumor invasion-associated factor downstream of Akt signaling. Mol Cell Biol. 2004;24:3526–35. doi: 10.1128/MCB.24.8.3526-3535.2004.PubMedCrossRefGoogle Scholar
  7. 7.
    Ekstrand AI, Jönsson M, Lindblom A, Borg A, Nilbert M. Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Fam Cancer. 2010;9:125–9. doi: 10.1007/s10689-009-9293-1.PubMedCrossRefGoogle Scholar
  8. 8.
    Li B, Tsao SW, Li YY, Wang X, Ling MT, Wong YC, et al. Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway. Int J Cancer. 2009;125:2576–85. doi: 10.1002/ijc.24675.PubMedCrossRefGoogle Scholar
  9. 9.
    Ohta T, Isobe M, Takahashi T, Saitoh-Sekiguchi M, Motoyama T, Kurachi H. The Akt and ERK activation by platinum-based chemotherapy in ovarian cancer is associated with favorable patient outcome. Anticancer Res. 2009;29:4639–47.PubMedGoogle Scholar
  10. 10.
    Simon Jr PO, McDunn JE, Kashiwagi H, Chang K, Goedegebuure PS, Hotchkiss RS, et al. Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma. Int J Cancer. 2009;125:942–51. doi: 10.1002/ijc.24424.PubMedCrossRefGoogle Scholar
  11. 11.
    Suzuki A, Kusakai G, Kishimoto A, Lu J, Ogura T, Esumi H. ARK5 suppresses the cell death induced by nutrient starvation and death receptors via inhibition of caspase 8 activation, but not by chemotherapeutic agents or UV irradiation. Oncogene. 2003;22:6177–82.PubMedCrossRefGoogle Scholar
  12. 12.
    Liu Z, Li L, Yang Z, Luo W, Li X, Yang H, et al. Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma. BMC Cancer. 2010;10:270. doi: 10.1186/1471-2407-10-270.PubMedCrossRefGoogle Scholar
  13. 13.
    Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26:2707–16. doi: 10.1200/JCO.2007.15.6521.PubMedCrossRefGoogle Scholar
  14. 14.
    Kelly K, Crowley J, Bunn Jr PA, Presant CA, Grevstad PK, Moinpour CM, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210–8.PubMedGoogle Scholar
  15. 15.
    Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004;5:341–53.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Department of GastroenterologyThe Second Affiliated Hospital of Zhengzhou UniversityZhengzhouChina
  2. 2.Department of Medical AdministrationGeneral Hospital of Chinese People’s Armed Police ForcesBeijingChina

Personalised recommendations